Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer

OBJECTIVE: Immunotherapy has not yielded satisfactory therapeutic responses in gastric cancer (GC). However, targeting myeloid checkpoints holds promise for expanding the potential of immunotherapy. This study aims to evaluate the critical role of Siglec-10(+) tumor-associated macrophages (TAMs) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Kunpeng, Sun, Mengyao, Fang, Hanji, Wang, Jieti, Lin, Chao, Liu, Hao, Zhang, Heng, Li, He, He, Hongyong, Gu, Yun, Li, Ruochen, Shao, Fei, Xu, Jiejie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649907/
https://www.ncbi.nlm.nih.gov/pubmed/37935567
http://dx.doi.org/10.1136/jitc-2023-007669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649907/
https://www.ncbi.nlm.nih.gov/pubmed/37935567
http://dx.doi.org/10.1136/jitc-2023-007669

Ejemplares similares